307 related articles for article (PubMed ID: 17934347)
21. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
[TBL] [Abstract][Full Text] [Related]
22. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
Taube T; Schmid H; Reinhard H; von Stackelberg A; Overberg US
Haematologica; 2005 Feb; 90(2):281-3. PubMed ID: 15710595
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
24. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
[TBL] [Abstract][Full Text] [Related]
25. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
[TBL] [Abstract][Full Text] [Related]
26. Refractory immune thrombocytopenic purpura: current strategies for investigation and management.
Psaila B; Bussel JB
Br J Haematol; 2008 Oct; 143(1):16-26. PubMed ID: 18573111
[TBL] [Abstract][Full Text] [Related]
27. Rapid encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura.
Golla S; Horkan C; Dogaru G; Teske TE; Christopher K
Acta Haematol; 2008; 120(2):100-3. PubMed ID: 18957844
[TBL] [Abstract][Full Text] [Related]
28. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
29. Comparison of intravenous immunoglobulin and high dose anti-D immunoglobulin as initial therapy for childhood immune thrombocytopenic purpura.
Ozsoylu S
Br J Haematol; 2011 Mar; 152(6):783-4. PubMed ID: 21275947
[No Abstract] [Full Text] [Related]
30. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?
Crow AR; Lazarus AH
Transfus Med Rev; 2008 Apr; 22(2):103-16. PubMed ID: 18353251
[TBL] [Abstract][Full Text] [Related]
31. ITP: a new regulatory issue!
Semple JW
Eur J Haematol; 2007 Oct; 79(4):279-80. PubMed ID: 17725611
[No Abstract] [Full Text] [Related]
32. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura.
Benedetti L; Franciotta D; Beronio A; Cadenotti L; Gobbi M; Mancardi GL; Schenone A; Tartaglione A
Muscle Nerve; 2008 Aug; 38(2):1076-7. PubMed ID: 18642360
[No Abstract] [Full Text] [Related]
33. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
Lee JW; Kim HA; Sung JM; Suh CH
Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
[No Abstract] [Full Text] [Related]
34. Recent advances in the treatment of idiopathic thrombocytopenic purpura: the anti-D clinical experience.
Bussel JB
Semin Hematol; 1998 Jan; 35(1 Suppl 1):1-4. PubMed ID: 9523742
[No Abstract] [Full Text] [Related]
35. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura.
Fianchi L; Rossi E; Murri R; De Stefano V; Pagano L; Leone G
Ann Hematol; 2007 Mar; 86(3):225-6. PubMed ID: 17031685
[No Abstract] [Full Text] [Related]
36. Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura.
Christopher K; Horkan C; Barb IT; Arbelaez C; Hodgdon TA; Yodice PC
Am J Hematol; 2004 Nov; 77(3):299-302. PubMed ID: 15495245
[TBL] [Abstract][Full Text] [Related]
37. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
38. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab.
Stosic M; De Jesus P; McCarthy J; Hutton G; Rivera V
Neurology; 2011 Aug; 77(5):505-7. PubMed ID: 21775738
[No Abstract] [Full Text] [Related]
39. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
40. Rituximab is effective in the treatment of refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia.
Oo TH
South Med J; 2005 Dec; 98(12):1227-8. PubMed ID: 16440930
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
